Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring
Theranostics · 2026
DOI: 10.7150/thno.123741 ↗At a glance
Journal article in Theranostics, 2026. Written by Michael Willmann and 9 co-authors. Institution: Department of Nuclear Medicine, Hannover Medical School, Germany. Major MEDLINE topics: Proto-Oncogene Proteins p21(ras), Positron-Emission Tomography, Fluorine Radioisotopes. Cited 1 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Ebda abstract disponibbli.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nuclear Medicine, Hannover Medical School, Germany.
- Merck Healthcare KGaA, Darmstadt, Germany.
Cite
APA
Willmann, M., Bankstahl, J. P., Bengel, F. M., Drechsler, C., Esdar, C., Gläser, K., Lopez, A. U., Ross, T., Schieferstein, H., & Ross, T. L. (2026). Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring. Theranostics. https://doi.org/10.7150/thno.123741
Vancouver
Willmann M, Bankstahl JP, Bengel FM, Drechsler C, Esdar C, Gläser K, et al. Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring. Theranostics. 2026. doi:10.7150/thno.123741
BibTeX
@article{Willmann2026,
author = {Willmann, Michael and Bankstahl, Jens P and Bengel, Frank M and Drechsler, Christine and Esdar, Christina and Gläser, Kathrin and Lopez, Andrea U and Ross, Tatjana and Schieferstein, Hanno and Ross, Tobias L},
title = {Development and in vivo evaluation of 18 F-labeled PET tracers covalently targeting KRAS-G12C for noninvasive cancer diagnosis and therapy monitoring},
journal = {Theranostics},
year = {2026},
doi = {10.7150/thno.123741}
}
EUVIMED